home All News open_in_new Full Article

Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company

SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) — Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today announced the successful close of the sale of its FXR program, including lead asset FXR314, to Eli Lilly and Company (NYSE:LLY) (“Lilly”).   […]


today 3 d. ago attach_file Economics

attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Economics
attach_file Economics
attach_file Politics
attach_file Culture
attach_file Culture
attach_file Other
attach_file Economics
attach_file Society
attach_file Transport
attach_file Other
attach_file Economics
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other


ID: 1963803377
Add Watch Country

arrow_drop_down